Volume | 408,659 |
|
|||||
News | - | ||||||
Day High | 11.75 | Low High |
|||||
Day Low | 11.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
KalVista Pharmaceuticals Inc | KALV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.53 | 11.28 | 11.75 | 11.50 | 11.65 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,141 | 408,659 | $ 11.57 | $ 4,729,583 | - | 7.21 - 16.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:35:40 | 6 | $ 11.23 | USD |
KalVista Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
485.59M | 42.19M | - | 0 | -92.91M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
KalVista Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KALV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.87 | 12.26 | 11.28 | 11.85 | 328,590 | -0.37 | -3.12% |
1 Month | 12.30 | 12.70 | 10.70 | 11.54 | 534,669 | -0.80 | -6.50% |
3 Months | 12.50 | 16.88 | 10.70 | 13.64 | 853,851 | -1.00 | -8.00% |
6 Months | 9.45 | 16.88 | 7.21 | 12.60 | 573,240 | 2.05 | 21.69% |
1 Year | 8.03 | 16.88 | 7.21 | 11.79 | 402,716 | 3.47 | 43.21% |
3 Years | 24.30 | 30.70 | 4.12 | 12.22 | 316,327 | -12.80 | -52.67% |
5 Years | 25.29 | 45.00 | 4.12 | 16.50 | 286,032 | -13.79 | -54.53% |
KalVista Pharmaceuticals Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. |